Home > Browse Research > Life Sciences > Pharmaceuticals > Regulation & Policy

Regulation & Policy: market research reports

Regulation & Policy market research reports and industry analysis

Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 9/1/2011 \| published by: GBI Research ... Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets”, which provides insights into drivers, barriers and trends in the outsourcing of ... \| read more...	$3,500.00
Pharmaceutical Market in India by 2020: A Healthy Decade 9/1/2011 \| published by: IKON Marketing Consultants ... player along with the global pharma market overview. The chapter 3 throws light on how the current decade going to remain healthy for the Indian pharma Industry followed by Chapter4 regulatory environment stating various laws ... \| read more...	$350.00
Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets 8/31/2011 \| published by: GBI Research ... Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets”, which provides insights regarding the comparative analysis of marketed drugs based on safety, efficacy, cost ... \| read more...	$3,500.00
Generics: Regulatory Update 8/30/2011 \| published by: Datamonitor ... countries in terms of GMP certification and free trade agreements will benefit the generics players, particularly in emerging markets.An overview of the impact of cost containment strategies on the generics industry. An examination of how ... \| read more...	$1,900.00
Pharmacovigilance and Related Developments 2011-2021 8/22/2011 \| published by: Visiongain ... and analysis we aim to save you time and help in your decisions. How will changes affect pharmacovigilance? What are drug producers and service providers doing? What regulations and technologies influence that field? Our study ... \| read more...	$2,416.00
Biosimilar: Regulatory Update 8/9/2011 \| published by: Datamonitor ... the EU, the EMA is furthering development of approval pathways for biosimilar monoclonal antibodies Features and benefits Provides global biosimilar sales (2008-10), in addition to the status of biosimilar approval pathways across the globe. Insight ... \| read more...	$395.00
Excipients in Pharmaceuticals 8/4/2011 \| published by: BCC Research ... at a compound annual growth rate (CAGR) of 6.5%. The market for organic chemicals was at $4.3 billion approximately in 2010 and it is expected to reach at $4.5 billion in 2011. It is further ... \| read more...	$5,450.00
Pharmaceutical Contract Manufacturing And Api Sourcing In Central Europe And The Balkan States 8/1/2011 \| published by: PMR ... Czech Republic, Slovakia, Hungary, Poland, Romania and Bulgaria and three Balkan states: Croatia, Serbia and Slovenia. The report examines current and future trends in contract manufacturing in the whole of the region and describes key ... \| read more...	$3,558.06
The World Pharmaceutical Markets Fact Book 2011 7/31/2011 \| published by: Espicom Healthcare Intelligence ... quickly those questions that arise daily, is essential. Therefore an authoritative, current and comprehensive market intelligence source is an invaluable aid for every executive. And that source is The World Pharmaceutical Markets Fact Book 2011. \| read more...	$865.00
South Korea: Healthcare System and Drug Regulatory Overview 7/28/2011 \| published by: Datamonitor ... to navigate, a relatively centralized structure allows for rapid responsiveness to changing conditions. Features and benefits Assess the key factors facing pharma in terms of healthcare expenditure, regulatory issues, pricing and reimbursement. Review the insurance ... \| read more...	$1,900.00
China Contract Research Organization (CRO) Industry Report, 2010-2011 7/20/2011 \| published by: Research in China ... saving. In 2010, the global market size of CRO achieved RMB36 billion, which undertook nearly one third of the R&D of new drugs. CRO industry started relatively late in China, and still in its initial ... \| read more...	$1,700.00
Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalate 7/19/2011 \| published by: Datamonitor ... only long term therapy approved in the US and Europe. As obese patient numbers rise, Datamonitor assesses the potential of late stage pipeline products to capitalize on a growing, unmet clinical need Features and benefits ... \| read more...	$11,400.00
Oncology Market Access in China – Market bolstered by rising incidence and improved regulatory environment 7/18/2011 \| published by: Datamonitor ... Chinese market more attractive for drug developers. Introduction An analysis of the key factors for success in China in the context of the overall healthcare industry An evaluation of the key active companies in the ... \| read more...	$5,700.00
Mexico: Healthcare System and Drug Regulatory Overview 7/14/2011 \| published by: Datamonitor ... 2012, through improving the intellectual property environment and eliminating similares. Pharmaceutical companies also stand to gain from the relatively unrestricted drug pricing environment in Mexico. Features and benefits Assess the key factors facing pharma in ... \| read more...	$1,900.00
R&D Trends: Neuropathic Pain - Extensive and diverse pipeline driven by high unmet need 7/13/2011 \| published by: Datamonitor ... expects to launch the drug in Q4 2011. Secondly, Horizant (gabapentin enacarbil; XenoPort/GlaxoSmithKline) obtained orphan drug status in the US for PHN in June 2011. Features and benefits Analysis of key R&D dynamics in the ... \| read more...	$3,800.00
Pharmaceutical Cliff Diving - Assessing the Key Challenges that will Re-Shape the Industry 7/1/2011 \| published by: CBR Pharma Insights, LLC ... big pharma, sales were flat to negative for most, but a number of companies found that their work to streamline and restructure were showing positive results, with Q1 profits up. The industry faces challenges from ... \| read more...	$3,900.00
Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market 7/1/2011 \| published by: GBI Research ... latest report, “Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market” which provides key data, information and analysis of the ... \| read more...	$3,500.00
Turkey: Healthcare System and Drug Regulatory Overview 7/1/2011 \| published by: Datamonitor ... on the US Trade Representative watch list. Also of concern to pharmaceutical companies is the drug discounting scheme as well as the reference pricing system, with further price cuts expected in 2011. Features and benefits ... \| read more...	$1,900.00
Global CRO Market: Quantitative Assessment 6/16/2011 \| published by: Frost & Sullivan ... purpose of this research service, the U.S. CRO markets include revenues derived from the preclinical and clinical services offered by CROs to pharmaceutical and biotechnology sponsors in conducting clinical trials. The markets are approached from ... \| read more...	$6,500.00
Maximizing Pharmaceutical Licensing Opportunities 6/14/2011 \| published by: Business Insights ... report also sets out future directions for licensing and alliance activity. Features and benefits Understand why licensing deals have become an integral part of Big Pharma strategies, along with the future impact of these strategies. ... \| read more...	$3,835.00
Impact of Counterfeits on Pharmaceutical Industry - Counterfeiting Poses Threats to Patient Safety and Revenues of Pharmaceutical Companies 6/10/2011 \| published by: GBI Research ... and Revenues of Pharmaceutical Companies”, provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the effects of counterfeits on the pharmaceutical industry in the US, Europe and the Rest of ... \| read more...	$3,500.00
Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition 6/1/2011 \| published by: JustPharmaReports.com ... strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget limitations, and growing demands for evidence of ... \| read more...	$2,300.00
Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS 5/24/2011 \| published by: GBI Research ... and Cancer Therapeutics are the Most Important Classes That Require REMS”, provides key data, information and analysis on the risk management and mitigation strategies, mandated by the FDA and being implemented by pharmaceutical companies. The ... \| read more...	$3,500.00
Outlook of China Drug Formulation Market 5/1/2011 \| published by: JZMed, Inc. ... industry has existed in China for decades and growing numbers of Chinese drug companies are currently focusing on this area, their current technical skills and capability are still limited. However, as the fast growing Chinese ... \| read more...	$3,285.00
A Comprehensive Guidebook for Foreign Pharmaceutical Companies China Pharmaceutical Guidebook Series (1) (4th edition) 5/1/2011 \| published by: Access China Management Consulting Ltd. ... regulations are variable and lack of transparency. Therefore, a comprehensive knowledge of the latest Chinese regulations for imported drug registration has been become an essential prerequisite for overseas pharmaceutical manufacturers and producers to achieve a ... \| read more...	$750.00

< prev 5 6 7 8 9 10 11 12 13 14 next >